Adipogen/Linagliptin/AG-CR1-3618-M010/10 mg
商品编号：
AG-CR1-3618-M010
品牌：
Adipogen Inc
市场价：
¥800.00
美元价：
480.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione; BI-1356 |
| Product Type | Chemical |
| Properties | |
| Formula |
C25H28N8O2 |
| MW | 472.5 |
| CAS | 668270-12-0 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (5mg/ml), ethanol or methanol. Slightly soluble in water (~1mg/ml). |
| InChi Key | LTXREWYXXSTFRX-QGZVFWFLSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Antidiabetic agent.
- Highly potent and selective competitive inhibitor of dipeptidyl-peptidase 4 (DPP4; DPP IV; CD26), an enzyme that degrades, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Prevents the inactivation of endogenous GLP-1 and GIP.
- Shown to restore β cell function and survival in human isolated islets through GLP-1 stabilization.
- Improves insulin sensitivity.
- Anti-inflammatory compound.
Product References
- 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes: M. Eckhardt, et al.; J. Med. Chem. 50, 6450 (2007)
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers: S. Hüttner, et al.; J. Clin. Pharmacol. 48, 1171 (2008)
- (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors: L. Thomas, et al.; J. Pharmacol. Exp. Ther. 325, 175 (2008)
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients: T. Heise, et al.; Diabetes Obes. Metab. 11, 786 (2009)
- The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice: J. Jelsing, et al.; J. Endocrinol. 214, 381 (2012)
- The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice: C. Schurmann, et al.; J. Pharmacol. Exp. Ther. 342, 71 (2012)
- Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity: M. Kern, et al.; PLoS One 7, e38744 (2012)
- Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes: B. Gallwitz; Diabetes Metab. Syndr. Obes. 6, 1 (2013) (Review)
- The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization: P. Shah, et al.; J. Clin. Endocrinol. Metab. 98, E1163 (2013)
- Linagliptin: from bench to bedside: J. Doupis; Drug. Des. Devel. Ther. 8, 431 (2014) (Review)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
